DCPH Company Profile and Key Details
NASDAQ : DCPH
Deciphera Pharmaceuticals
$25.59
0.02+0.08%
At Close 4:00 PMNot Actively Trading
58.85
BESG ScoreESG Rating
Price Chart
Stock Price Today
Deciphera Pharmaceuticals, Inc. (DCPH) stock surged +0.08%, trading at $25.59 on NASDAQ, up from the previous close of $25.57. The stock opened at $25.56, fluctuating between $25.56 and $25.61 in the recent session.
Stock Snapshot
25.57
Prev. Close
2.21B
Market Cap
25.56
Day Low
-11.57918552036199
P/E Ratio
-2.21
EPS (TTM)
-1.7
Cash Flow per Share
25.56
Open
86.48M
Number of Shares
25.61
Day High
53.69%
Free Float in %
4.05
Book Value
1.57M
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 11, 2024 | 25.59 | 25.59 | 25.59 | 25.59 | 0 |
| Jun 10, 2024 | 25.56 | 25.61 | 25.56 | 25.59 | 1.59M |
| Jun 07, 2024 | 25.57 | 25.58 | 25.56 | 25.57 | 506.79K |
| Jun 06, 2024 | 25.58 | 25.58 | 25.55 | 25.55 | 1.22M |
| Jun 05, 2024 | 25.57 | 25.59 | 25.55 | 25.58 | 2.01M |
| Jun 04, 2024 | 25.56 | 25.57 | 25.55 | 25.57 | 510.52K |
| Jun 03, 2024 | 25.56 | 25.57 | 25.54 | 25.56 | 1.42M |
| May 31, 2024 | 25.52 | 25.56 | 25.52 | 25.54 | 1.85M |
| May 30, 2024 | 25.53 | 25.54 | 25.51 | 25.53 | 701.01K |
| May 29, 2024 | 25.51 | 25.53 | 25.51 | 25.51 | 1.06M |
| May 28, 2024 | 25.52 | 25.54 | 25.51 | 25.51 | 1.09M |
| May 24, 2024 | 25.52 | 25.53 | 25.51 | 25.51 | 553.79K |
| May 23, 2024 | 25.52 | 25.52 | 25.49 | 25.50 | 1.06M |
| May 22, 2024 | 25.53 | 25.53 | 25.47 | 25.48 | 1.76M |
| May 21, 2024 | 25.46 | 25.49 | 25.46 | 25.47 | 1.08M |
| May 20, 2024 | 25.47 | 25.48 | 25.45 | 25.47 | 851.18K |
| May 17, 2024 | 25.46 | 25.47 | 25.44 | 25.46 | 1.15M |
| May 16, 2024 | 25.46 | 25.46 | 25.43 | 25.45 | 1.43M |
| May 15, 2024 | 25.47 | 25.48 | 25.44 | 25.45 | 970.46K |
| May 14, 2024 | 25.44 | 25.47 | 25.40 | 25.44 | 4.96M |
Contact Details
About Company
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients. Their core strategy involves tackling the mechanisms of drug resistance that often limit the effectiveness and longevity of current cancer treatments, serving markets both domestically and internationally. The company's flagship product, QINLOCK, is employed in the treatment of gastrointestinal stromal tumors (GIST) and is additionally undergoing a Phase 3 clinical trial (INTRIGUE study) for second-line GIST. Deciphera's pipeline also includes vimseltinib, a potent, orally available, and highly selective switch-control kinase inhibitor targeting colony stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT). Furthermore, they are advancing DCC-3116, currently in preclinical development, which targets RAS/RAF mutant cancers. Established in 2003, Deciphera Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Company Information
| Employees | 355 |
| Beta | 0.18 |
| Sales or Revenue | $163.36M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Stock Peers
ITCI
00
Intra-Cellular Therapies, Inc.$131.87LNTH2.34+2.25%
Lantheus Holdings, Inc.$106.20ANIP1.09+1.37%
ANI Pharmaceuticals, Inc.$80.58SUPN0.1+0.23%
Supernus Pharmaceuticals, Inc.$44.48HROW-0.46-1.07%
Harrow Health, Inc.$42.41INDV0.02+0.05%
Indivior Pharmaceuticals Inc$38.32COLL-0.09-0.27%
Collegium Pharmaceutical, Inc.$33.45PAHC-0.78-2.45%
Phibro Animal Health Corporation$31.07PETQ-0.01-0.03%
PetIQ, Inc.$30.98ASRT00
Assertio Holdings, Inc.$23.50Company Overview
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) closed at $25.59 USD, gaining $0.02 (0.08%) from the previous close of $25.57. The stock is currently trading near its 52-week high $9.90 and $25.61. With a market capitalization of about $2.21 billion, Deciphera Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.18). Key stats such as the average daily volume over the past year has been around 1.86 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Deciphera Pharmaceuticals, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Steven L. Hoerter, the company employs approximately 355 people and listed since September 28, 2017. Deciphera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing innovative therapies to significantly improve outcomes for cancer patients.
Technical Performance
Short-term trend indicators are bearishly aligned (SMA20 0.32%, SMA50 20.33%, SMA200 61.93%). The stock’s 14-day RSI is 85.58 (overbought), while the ATR of 0.2 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.08% below its high and over 158.48% above its low.
Valuation Metrics
Deciphera Pharmaceuticals, Inc. trades at a P/E ratio of -11.17, slightly below the S&P 500 average, with a price-to-sales ratio of 13.55 and a price-to-book ratio of 6.2 trading at moderately above to book value. The P/FCF stands at -15.01, also below market averages.
Dividend & Fair Value
Deciphera Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $17.21. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Deciphera Pharmaceuticals, Inc. generated EPS of -$2.21 over the past year. Five-year average earnings growth is 4.07%. Wall Street analysts project EPS growth of 21.0% annually over the next five years. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at -$0.51. Next year's EPS is expected at $1.13. Deciphera Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 10, 2024, missed forecasts by -5.45%. The prior quarter beat by -6.9%. Over the last six quarters, Apple has recorded several small beats. These include 7.14% in February 07, 2023.
Shareholding & Insider Activity
Deciphera Pharmaceuticals, Inc. has 86.48 million shares outstanding. The public float is 46.43 million shares, elevated short interest at 6.33% of float. This equals 3.92 million shares. The short ratio is 1.05 days. Institutional investors hold 100.72% of the float. Insiders own 28.48%. Brightstar Associates LLC holds 19.72 million shares, Sherman Matthew L has 108.74 thousand shares and Kelly Thomas Patrick has 80.35 thousand shares.
Price Forecast & Outlook
Our AI price prediction model suggests that Deciphera Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 14.15%, with price expected at $29.21 by June 25, 2024, within a range of $25.36 to $32.55 3-Month Outlook: Projected fall of -34.58%, reaching $16.74 by September 09, 2024, with a range of $15.63 to $17.85. 1-Year Outlook: Projected gain of 87.42%, with price at $47.96 by June 11, 2025, within a range of $44.51 to $51.40.
Key Takeaways
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares are up 58.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Deciphera Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -11.17. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $35.64, suggesting 39.27% upside. Our AI forecast model points to short-term strength (14.15% over two weeks), a medium-term fall (-34.58% over three months), and a longer-term gain (87.42% over one year), with expected trading ranges indicating moderate volatility.
Frequently Asked Questions
What is the current Deciphera Pharmaceuticals, Inc. (DCPH) stock price?
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) stock price is $25.59 in the last trading session. During the trading session, DCPH stock reached the peak price of $25.61 while $25.56 was the lowest point it dropped to. The percentage change in DCPH stock occurred in the recent session was 0.08% while the dollar amount for the price change in DCPH stock was $0.02.
DCPH's industry and sector of operation?
The NASDAQ listed DCPH is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Deciphera Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of DCPH?
Dr. Daniel L. Flynn Ph.D.
Executive Vice President, Chief Scientific Officer & Founder
Mr. Steven L. Hoerter
Pres, Chief Executive Officer & Director
Dr. Stephen B. Ruddy Ph.D.
Senior Vice President & Chief Technical Officer
Mr. Thomas Patrick Kelly J.D.
Executive Vice President, Chief Financial Officer & Treasurer
Jennifer Larson
Senior Vice President of Fin. & Investor Relations
Mr. Jeffrey M. Held J.D.
Senior Vice President & Gen. Counsel
Dr. Matthew L. Sherman M.D.
Executive Vice President & Chief Medical Officer
Mr. Daniel C. Martin
Senior Vice President & Chief Commercial Officer
Ms. Jama Pitman
Senior Vice President of Regulatory, Quality & Portfolio Management
Executive Vice President, Chief Scientific Officer & Founder
Mr. Steven L. Hoerter
Pres, Chief Executive Officer & Director
Dr. Stephen B. Ruddy Ph.D.
Senior Vice President & Chief Technical Officer
Mr. Thomas Patrick Kelly J.D.
Executive Vice President, Chief Financial Officer & Treasurer
Jennifer Larson
Senior Vice President of Fin. & Investor Relations
Mr. Jeffrey M. Held J.D.
Senior Vice President & Gen. Counsel
Dr. Matthew L. Sherman M.D.
Executive Vice President & Chief Medical Officer
Mr. Daniel C. Martin
Senior Vice President & Chief Commercial Officer
Ms. Jama Pitman
Senior Vice President of Regulatory, Quality & Portfolio Management
How DCPH did perform over past 52-week?
DCPH's closing price is 158.49% higher than its 52-week low of $9.90 where as its distance from 52-week high of $25.61 is -0.08%.
How many employees does DCPH have?
Number of DCPH employees currently stands at 355.
Link for DCPH official website?
Official Website of DCPH is: https://www.deciphera.com
How do I contact DCPH?
DCPH could be contacted at phone 781 209 6400 and can also be accessed through its website. DCPH operates from 200 Smith Street, Waltham, MA 02451, United States.
How many shares of DCPH are traded daily?
DCPH stock volume for the day was 1.57M shares. The average number of DCPH shares traded daily for last 3 months was 1.86M.
What is the market cap of DCPH currently?
The market value of DCPH currently stands at $2.21B with its latest stock price at $25.59 and 86.48M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep